ALSO NOTED: Flamel shares buoyed by partnership buzz; Medarex cuts stake in Genmab; Bush offers new stem cell funds; and much m

> Shares of France's Flamel Technologies were buoyed by an analyst's prediction that the company was nearing a late-stage partnering deal. Report

> Medarex has cut its stake in Genmab as analysts began raising some big questions over the possibility of a buyout. Report 

> During the State of the Union address, President Bush promised of new government funding for scientists advancing the uses of skin cells to replace embryonic stem cells in medical research. Report

> A team of scientists have spun off a company to commercialize a new chemical synthesis that they say can far more efficiently create and manufacture new compounds. Report

> Even as the demand for new antibiotics grows, new research programs to advance fresh therapies have been drying up fast. Report

> On a mission for more info on how companies set top execs' pay, the SEC has been pushing for details--and now it's knocking on doors at Bristol-Myers Squibb, Boston Scientific, and Baxter. Report

> Alfacell announced that 311 evaluable events (patient deaths) have occurred in the Phase IIIb clinical trial of its lead compound, ONCONASE, for unresectable malignant mesothelioma. Release 

> Roche just posted sales of $42.2 billion, $2.4 billion more than its Swiss rival Novartis' $39.8 billion. Report

> Merck reported a whopping $1.6 billion loss for the fourth quarter. Report

And Finally... Is synthetic biotechnology the next big thing in drug R&D? Report

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.